Pharming Group N.V. Investigation
Company: Pharming Group N.V.
Ticker: (NASDAQ) PHAR
Join the Pharming Group N.V. Investigation
Investigation Details
Pharming Group stock dropped 22% on July 30, 2026, after the Company reported second-quarter revenue of $90.2 million -- down 3% year-over-year -- and cut its full-year 2026 revenue guidance to $375-$395 million from $405-$425 million.
The revenue shortfall was primarily driven by RUCONEST, the Company's legacy hereditary angioedema therapy. RUCONEST sales fell 10% year-over-year to $72.3 million in the quarter. Joenja revenue rose 40% to $17.9 million. Diluted EPS came in at $0.002, versus $0.006 in the prior-year period.
The reduced FY 2026 outlook sits roughly $30 million below the prior midpoint and below analyst consensus of approximately $419 million. This investigation concerns whether Pharming Group and certain of its officers may not have adequately disclosed competitive and demand pressures affecting RUCONEST prior to the July 30, 2026 announcement.